The FDA has nixed Epix Pharmaceuticals’ appeal of its earlier decision to call for more data regarding the MR blood pool agent Vasovist. The company had asked the agency to approve Vasovist or, alternatively, to refer its request for approval to an FDA advisory committee. The FDA declined both.
The FDA has nixed Epix Pharmaceuticals' appeal of its earlier decision to call for more data regarding the MR blood pool agent Vasovist. The company had asked the agency to approve Vasovist or, alternatively, to refer its request for approval to an FDA advisory committee. The FDA declined both.
FDA reviewers last year issued an "approvable letter" for the agent, but stated that final approval would hinge on submission of additional clinical data to demonstrate its efficacy (DI SCAN, 1/24/05, FDA approvable letter spells bad news for Epix Medical).
In its response, the company tried unsuccessfully to convince reviewers to accept just the data initially submitted. This led to the appeal, filed this year.
In the FDA's response to this appeal, which the company described Aug. 28, the agency suggested that, "If Epix decides to conduct additional clinical research to support approval, rather than relying on a blinded reread of previously submitted data and data from a new clinical trial, a safer course of action would be to conduct two new clinical trials to support the application for approval."
The company might not take the FDA's advice. Epix is exploring several options, according to Andrea Johnston, a spokesperson for the company. Appealing the denial to the next level of the FDA, the Center for Drug Evaluation and Research, is one of those options, she said.
The company first submitted its application to the imaging division, then appealed to the Office of New Drugs, Johnston said. The CDER represents the next level, she said.
Another option, she said, is to conduct more clinical tests to support the data submitted with the application. Before making a decision about which option to choose, the company plans to consult with its board, according to Johnston.
"They will try to make this decision sooner rather than later," she said.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.